GHR and diabetic kidney disease: Treatment with GH antagonists or somatostatin analogs, as well as genetic disruption or pharmacological blockade of the GHR, resulted in amelioration of experimental diabetic nephropathy, including normalization of diabetes-associated renal hypertrophy and glomerular enlargement, as well as albuminuria [203, 207–210].